Results 71 to 80 of about 10,720 (171)
FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
Teresa Krakauer Department of Immunology, Molecular Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA Abstract: Immunostimulating staphylococcal enterotoxin B (SEB)
Krakauer T
doaj
Background: Group A Streptococcus (GAS) is a human pathogen that causes various diseases ranging from localised infections to toxin- and immune-mediated conditions.
Matete O. Kgasha +5 more
doaj +1 more source
Staphylococcal Enterotoxin C2 (SEC2), a classical superantigen, is an antitumor immunotherapy agent. However, the injectable formulation of SEC2 limits its clinical application.
Wu Gu +9 more
doaj +1 more source
The development of immune cell engagers (ICEs) can be limited by logistical and functional restrictions associated with fusion protein designs, thus limiting immune cell recruitment to solid tumors.
Yao‐An Yu +7 more
doaj +1 more source
Bacterial Superantigen-Mediated Toxic Shock: Hyperinflammatory Trajectories and Extracorporeal Immunomodulation in Streptococcal Toxic Shock Syndrome. [PDF]
Lo KH, Lu KC, Liu YH, Hou YC.
europepmc +1 more source
Superantigens as Contributors to the Etiology of Kawasaki Disease Shock Syndrome. [PDF]
Yamazaki-Nakashimada MA +8 more
europepmc +1 more source

